HIV Protease Inhibitor Use During Pregnancy Is Associated With Decreased Progesterone Levels, Suggesting a Potential Mechanism Contributing to Fetal Growth Restriction

Background. Protease inhibitor (PI)–based combination antiretroviral therapy (cART) is administered during pregnancy to prevent perinatal human immunodeficiency virus (HIV) transmission. However, PI use has been associated with adverse birth outcomes, including preterm delivery and small-for-gestati...

Descripción completa

Detalles Bibliográficos
Autores principales: Papp, Eszter, Mohammadi, Hakimeh, Loutfy, Mona R., Yudin, Mark H., Murphy, Kellie E., Walmsley, Sharon L., Shah, Rajiv, MacGillivray, Jay, Silverman, Michael, Serghides, Lena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2015
Materias:
Major Articles and Brief Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4264589/
https://www.ncbi.nlm.nih.gov/pubmed/25030058
http://dx.doi.org/10.1093/infdis/jiu393

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4264589/
https://www.ncbi.nlm.nih.gov/pubmed/25030058
http://dx.doi.org/10.1093/infdis/jiu393

Ejemplares similares